Peptides & the FDA review: your questions, answered

Some human studies report that MOTS-c levels increase with exercise, and that lower levels correlate with obesity and higher fasting insulin. These are associations from observational research, not proof that supplementing MOTS-c produces a health benefit.¹

The FDA-evaluated uses listed for MOTS-c are obesity and osteoporosis.²

MOTS-c is not an FDA-approved drug and has no cleared compounding pathway. It was in Category 2 of the interim 503A list, then removed in April 2026 and referred to the July 2026 advisory committee. Removal did not place it on the approved list.^{2 3 4}